LONDON–(BUSINESS WIRE)–Technavio has been monitoring the global idiopathic intracranial hypertension therapeutics market and the market is poised to grow by USD 15.34 million during 2019-2023, progressing at a CAGR of almost 3% during the forecast period. Request Free Sample Pages
Read the 153-page research report with TOC on “Idiopathic Intracranial Hypertension Therapeutics Market Analysis Report by Geography (Asia, Europe, North America, and ROW), by Product (Carbonic anhydrase inhibitors and Other drug classes), and Segment Forecasts, 2019-2023”.
The market is driven by the rising incidence of idiopathic intracranial hypertension. In addition, the increasing number of awareness campaigns are anticipated to further boost the growth of the idiopathic intracranial hypertension therapeutics market.
Developed economies such as the US and other countries are witnessing a high incidence of obesity and cardiovascular disorders, which has increased the patient pool for idiopathic intracranial hypertension. This has increased the need for immediate therapeutic interventions such as idiopathic intracranial hypertension therapeutics. Thus, the rising incidence of idiopathic intracranial hypertension is expected to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Idiopathic Intracranial Hypertension Therapeutics Market Companies:
AbbVie Inc. is headquartered in the US and operates the business through its Pharmaceutical products segment. The company offers Acetazolamide, which is a carbonic acid anhydrase, used for the treatment of idiopathic intracranial hypertension and other various diseases.
Astellas Pharma Inc.
Astellas Pharma Inc. is headquartered in Japan and offers products through its business unit, Pharmaceuticals. This segment focuses on the commercialization, development, manufacture, and discovery of therapeutics for the treatment of various indications.
Cadila Healthcare Ltd.
Cadila Healthcare Ltd. is headquartered in India and has business operations under its product segment: Pharmaceuticals. Linagliptin and metformin hydrochloride tablets, developed by the company have received tentative approval from the US FDA.
Johnson & Johnson Services Inc.
Johnson & Johnson Services Inc. is headquartered in the US and offers services through the following segments: Consumer, Pharmaceutical, and Medical devices. The company offers TOPAMAX, which is an antiepileptic drug that is used to treat idiopathic intracranial hypertension.
Merck & Co., Inc.
Merck & Co. Inc. is headquartered in the US and offers services through the following business segments: Pharmaceutical, Animal health, and Other. The company has launched KEYTRUDA as it has recently received approval from the US FDA.
Register for a free trial today and gain instant access to 10,000+ market research reports.
Technavio’s SUBSCRIPTION platform
Idiopathic Intracranial Hypertension Therapeutics Product Outlook (Revenue, USD Million, 2019-2023)
- Carbonic anhydrase inhibitors
- Other drug classes
Idiopathic Intracranial Hypertension Therapeutics Regional Outlook (Revenue, USD Million, 2019-2023)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Health Care are:
Sarcoma Therapeutics Market – Global Sarcoma Therapeutics Market by type (soft tissue sarcoma and osteosarcoma) and geography (the Americas, APAC, and EMEA).
Peptide Therapeutics Market – Global Peptide Therapeutics Market by RoA (parenteral, oral, and others) and geography (the Americas, APAC, and EMEA).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.